17th International Congress on Infectious Diseases

Cutterguide: N/A Printing Process: Offset
GD: 35216
Size: (W) 215.9 x (H) 297.4 mm) Pages: 1 Colors: C M Y K (4 Colors)
Native File: Indesign CC Windows Generated in: Acrobat Distiller 11
ICID 2016
GSK satellite symposia
Save the dates
Pertussis.
The protection starts with you.
Thursday March 3, 2016
12.30 - 14.15, Hall 6
Do MMRV combination vaccines
optimise the prevention of measles,
mumps, rubella and varicella?
Friday March 4, 2016
18.00 - 20.00, Hall 6
Following the successes of vaccination in the 20 th Century, we need to be more than ever prepared to support
and convey the value of vaccination against measles, mumps, rubella, varicella and pertussis in certain age
groups. 1 During recent years there has been a series of outbreaks of pertussis, measles and mumps, mainly
due to insufficient vaccine and booster vaccine coverage. 2,3,4
The symposium “Pertussis. The prevention starts with you” will be chaired by Dr Sundaram Balasubramanian,
Head of the Department of Pediatrics at Kanchi Kamakoti CHILDS Trust Hospital and Medical Research
Foundation, Chennai, India. During a round table discussion the faculty, composed of the GSK experts
Dr Anil Dutta, Vice-President & Head, Medical and Clinical - Emerging Markets, Dr Walid Kandeil and Dr Tomas
Marcek, Senior Managers Global Medical Affairs for DTP combination vaccines, will address from a global and
regional perspective the epidemiology of pertussis, discuss experiences with strategies adopted for optimising
pertussis control, as well as recently published data and unmet medical needs.
The GSK symposium “Do MMRV combination vaccines optimise the prevention of measles, mumps,
rubella and varicella?” is designed to tackle some of the burning questions on Measles, Mumps, Rubella and
Varicella combination vaccines. Lessons learned all over the world with different MMR/V vaccination schedules
will be discussed as wel l as the safety aspects of combination vaccines. New Indian data will be presented
with the use of MMRV vaccine for the first time in a highly endemic measles setting. 5 The expert faculty
consisting of Dr Sanjay Lalwani, Department of Pediatrics, Bharati Vidyapeeth Deemed University, Pune, India,
Dr Anil Dutta GSK, Vice-President & Head, Medical and Clinical - Emerging Markets, and Dr Volker Vetter,
GSK, Global Medical Affairs Lead for MMRV vaccines will openly discuss different viewpoints.
Upgrade your knowledge on vaccines from the observations, insights and experiences of our expert speakers.
References:
1. Greenwood B. 2014, Phil. Trans. R. Soc. B 369: 20130433; 2. Tan T et al. Pediatr Infect Dis J 2015; 34: e222-e232. 3. Public trust in vaccines: defining a research
agenda, AAAS 2014 ISBN: 0-87724-098-1; 4. Sabbe M et al. Hum Vaccin lmmunother 2016 (epub); 5. Lalwani S et al. BMJ Open 2015; 5: e007202
Date of preparation: January 2016 VGBU/B00/0001/16a
GlaxoSmithKline Pharmaceuticals Limited, Dr. Annie Besant Road, Worli, Mumbai 400 030 (India).
Please report adverse events with any GSK product to the company at india.pharmacovigilance@gsk.com
© 2016 by GSK Biologicals. All rights reserved.
ICID_Newsletter_GSKDC-PT-GVAC-2016-290_D1.indd 1
2/8/2016 5:58:09 PM